Literature DB >> 18676566

Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.

James M Perrin, Richard A Friedman, Timothy K Knilans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18676566     DOI： 10.1542/peds.2008-1573

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  54 in total

1.  Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010.

Authors:  Craig F Garfield; E Ray Dorsey; Shu Zhu; Haiden A Huskamp; Rena Conti; Stacie B Dusetzina; Ashley Higashi; James M Perrin; Rachel Kornfield; G Caleb Alexander
Journal:  Acad Pediatr       Date:  2012-02-10       Impact factor: 3.107

2.  Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder.

Authors:  Martin P Cruz
Journal:  P T       Date:  2010-08

Review 3.  Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.

Authors:  Timothy E Wilens; Thomas J Spencer
Journal:  Postgrad Med       Date:  2010-09       Impact factor: 3.840

Review 4.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

Review 5.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Authors:  Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

6.  ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Authors:  Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser
Journal:  Pediatrics       Date:  2011-10-16       Impact factor: 7.124

7.  Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients.

Authors:  M Riera; X Castells; A Tobias; R Cunill; L Blanco; D Capellà
Journal:  Psychopharmacology (Berl)       Date:  2017-06-19       Impact factor: 4.530

8.  Cardiac risk assessment before the use of stimulant medications in children and youth.

Authors:  S A Bélanger; A E Warren; R M Hamilton; C Gray; R M Gow; S Sanatani; J M Côté; J Lougheed Frcpc; J Leblanc; S Martin; B Miles; C Mitchell; D A Gorman; M Weiss; R Schachar
Journal:  Paediatr Child Health       Date:  2009-11       Impact factor: 2.253

9.  Pharmacologic intervention for attention-deficit hyperactivity disorder in preschoolers : is it justified?

Authors:  Jaswinder K Ghuman; Harinder S Ghuman
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

10.  The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.

Authors:  Jason G Ho; Randall L Caldwell; Christopher J McDougle; Danielle K Orsagh-Yentis; Craig A Erickson; David J Posey; Kimberly A Stigler
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-07-31       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.